Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2014 /
Ovarian suppression with tamoxifen reduced recurrence in some premenopausal breast cancer cases

9th - 11th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.14
Views: 4450
Rating:

Dr Prudence Francis - Peter MacCallum Cancer Centre, Melbourne, Australia

At a press conference at SABCS 2014, Dr Prudence Francis presents data on adding ovarian suppression to tamoxifen reduced recurrence for some women with premenopausal breast cancer.

A 35 percent decrease in risk of breast cancer recurrence was observed for premenopausal women who received chemotherapy for early-stage, hormone receptor-positive breast cancer and were assigned exemestane with ovarian suppression compared with those assigned tamoxifen.

Read the news story or watch the interview for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation